2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
01/28/19UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK--(BUSINESS WIRE)--Jan. 28, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its previously announced public offering of 4,207,317 ordinary shares, including 548,780 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. All of the ordina... 
Printer Friendly Version
01/23/19UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
NEW YORK--(BUSINESS WIRE)--Jan. 23, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its public offering of 3,658,537 ordinary shares at a public offering price of $41.00 per share, for a total public offering size of approximately $150.0 million, before deducting underwriting discounts ... 
Printer Friendly Version
01/22/19UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
NEW YORK--(BUSINESS WIRE)--Jan. 22, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the... 
Printer Friendly Version
01/08/19UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
Data Demonstrates Complete Response (CR) Rate of 57 Percent in Patients with LG UTUC All Evaluated Patients in CR Remain Disease Free at Six Months Rolling Submission of New Drug Application (NDA) Initiated in December 2018 NEW YORK--(BUSINESS WIRE)--Jan. 8, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today annou... 
Printer Friendly Version
01/03/19UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
Ms. Barrett Most Recently Served as CEO for Novartis Oncology and Brings a Track Record of Success in Commercial Oncology NEW YORK--(BUSINESS WIRE)--Jan. 3, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Elizabeth (Liz) Barrett as President and Chief Executive Officer effect... 
Printer Friendly Version